Author

A. Freeman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 2 Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 4 Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Organism:mouse· 2 Approach:statistical model· 2

Frequent Co-Authors

A. Acha-Sagrado· 1 shared A. Bichisecchi· 1 shared A. E. Taylor· 1 shared A. J. Sinclair· 1 shared A. Kelly· 1 shared A. Laurence· 1 shared A. Malik· 1 shared A. Mendez· 1 shared

Activity by Year

2017-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 9 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Acha-Sagrado

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of oesophageal cancer

P. Ganguli, C. Colomina-Basanta, A. Acha-Sagrado, H. Misetic, M. Armero-Pineiro, A. Mendez, A. Zahra, G. Devonshire, G. Kelly, A. Freeman, M. Green, E. Nye, A. Bichisecchi, P. Bonfanti, Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, , F. D. Ciccarelli

The paper investigates how CDKN2A and other 9p21 gene losses influence oesophageal cancer progression, finding context-dependent effects on survival and immune infiltration.

bioRxiv · Jan 24, 2024 · PreprintCancer Biology

Inhibition of the glucocorticoid-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 drives concurrent 11-oxygenated androgen excess

L. Schiffer, I. Oestlund, J. Snoep, L. C. Gilligan, A. E. Taylor, A. J. Sinclair, R. Singhal, A. Freeman, R. Ajjan, A. Tiganescu, W. Arlt, K.-H. Storbeck

This study shows that inhibiting HSD11B1 increases 11-ketotestosterone levels in adipose tissue and circulation, potentially offsetting benefits of reduced glucocorticoid activation in women.

bioRxiv · Jun 5, 2023Biochemistry

An inactivated multivalent influenza A virus vaccine is broadly protective in mice and ferrets

J. Park, S. Fong, L. M. Schwartzman, Z.-M. Sheng, A. Freeman, L. Matthews, Y. Xiao, M. D. Ramuta, N. A. Batchenkova, L. Qi, L. A. Rosas, S. Williams, K. Scherler, M. Gouzoulis, I. Bellayr, , J. K. Taubenberger

This study shows an inactivated multivalent influenza A vaccine provides broad protection against diverse IAV subtypes in mice and ferrets, including non-vaccine strains, suggesting its potential as a universal vaccine.

bioRxiv · Sep 10, 2021Microbiology

An autocrine Vitamin D-driven Th1 shutdown program can be exploited for COVID-19

R. McGregor, D. Chauss, T. Freiwald, B. Yan, L. Wang, E. Nova-Lamperti, Z. Zhang, H. Teague, E. West, J. Bibby, A. Kelly, A. Malik, A. Freeman, D. Schwartz, D. Portilla, , B. Afzali

This study identifies a Vitamin D-driven mechanism that suppresses excessive Th1 responses in COVID-19, suggesting potential therapeutic use of Vitamin D analogs.

bioRxiv · Jul 18, 2020 · PreprintImmunology

Modulation of T helper 1 and T helper 2 immune balance in a stress mouse model during Chlamydia muridarum genital infection

T. BELAY, E. Martin, G. Brown, R. Crenshaw, J. Street, A. Freeman, S. Musick, T. Kinder

This study shows cold-induced stress modulates Th1/Th2 balance in mice infected with Chlamydia muridarum by increasing Th2 cytokines and decreasing Th1 cytokines.

bioRxiv · Dec 4, 2019Microbiology

Ruxolitinib partially reverses functional NK cell deficiency in patients with STAT1 gain-of-function mutations

A. Vargas Hernandez, E. M. Mace, O. Zimmerman, C. Zerbe, A. Freeman, S. Rosenzweig, J. W. Leiding, T. Torgerson, M. C. Altman, E. Schussler, C. Cunningham-Rundles, I. K. Chinn, I. C. Hanson, N. L. Rider, S. M. Holland, , L. R. Forbes

This study shows that ruxolitinib partially restores NK cell function in STAT1 GOF patients by reducing STAT1 phosphorylation and improving cytotoxic activity.

bioRxiv · Jun 28, 2017Immunology